Clinical trial · Observational
The Adjuvant Effect of HPV Vaccination on Recurrence of Cervical Precancer or Carcinoma in Women Undergoing Conization
The Adjuvant Effect of HPV Vaccination on Recurrence of Cervical Intraepithelial Neoplasia Grade 2 or Worse in Women Undergoing Conization: Retrospective Cohort Study
NCT06258564CI-TRIAL-00085936completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Assessment of the association between human papillomavirus vaccination (HPV) and recurrences of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) in women undergoing conization.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Intraepithelial Neoplasia Grade 2/3 | Cervical Intraepithelial Neoplasia Grade 2/3 | ONTOLOGY_EXACT | 0.98 |
| Recurrence | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| vaccination against human papillomavirus infection (HPV vaccination) | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- single cohort of women with cervical excision for CIN2+
- description
- single cohort of women with cervical excision for CIN2+; those with HPV vaccination and those without HPV vaccination
- interventionNames
- Biological: vaccination against human papillomavirus infection (HPV vaccination)
Primary outcomes (1)
- measure
- CIN2+ recurrence rate
- timeFrame
- 2010-2024
- description
- CIN2+ recurrence rate - obtained from the number of women with this find-ing related the number of women with no finding within the time period since the conization; The recurrence rate of CIN2+ will be assessed in relation to vaccination, vaccine type, vaccination completeness, etc., using specific uni-variate analysis (incidence rate ratio) and multivariate analysis (incidence rate ratio or hazard ratio, as appropriate)
Secondary outcomes (1)
- measure
- CIN2+ recurrence frequency
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * Women \>18 years, with conization for CIN2+ (HSIL) * Women who had more than one examination during a follow-up period of \>6 months. Exclusion Criteria: \- Women who underwent hysterectomy after conization. * Women who had excision procedures other than cervical excision. * Women who did not undergo any other cytological/histological examinations. * Women with more than one conization before CIN2+ recurrence
References
Publications (1)
- RESULTPetras M, Dvorak V, Lomozova D, Macalik R, Neradova S, Dlouhy P, Malinova J, Rosina J, Lesna IK. Timing of HPV vaccination as adjuvant treatment of CIN2+ recurrence in women undergoing surgical excision: a meta-analysis and meta-regression. Sex Transm Infect. 2023 Dec;99(8):561-570. doi: 10.1136/sextrans-2023-055793. Epub 2023 Aug 8. PMID 37553234